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1. Introduction 
Pulmonary hypertension (PH) is a serious complication of sarcoidosis, a multi-systemic 
inflammatory disease characterized by the presence of widespread non-caseating 
granulomas. When PH develops in patients with sarcoidosis, it is associated with increased 
morbidity and mortality.  
Sarcoidosis-associated pulmonary hypertension (SAPH) is most commonly seen in patients 
with advanced pulmonary sarcoidosis as a result of pulmonary fibrosis and chronic 
hypoxemia. However, the presence of PH in individuals with extra-pulmonary sarcoidosis 
and normal pulmonary physiology suggests that SAPH may be due to other mechanisms. 
Appropriate understanding of this disease and its complex pathophysiology is essential for 
early recognition and therapy.  
2. Definition  
SAPH is defined as mean pulmonary artery pressure (mPAP) above 25 mm Hg at rest with a 
pulmonary artery occlusion pressure (PAOP) or left ventricular end-diastolic pressure 
(LVEDP) less than 15 mmHg, in patients with sarcoidosis, diagnosed by clinical, radiological 
and histological criteria, in the absence of other risk factors for pulmonary hypertension. 
(Badesch et al., 2009) Because of the complex pathogenetic mechanisms of SAPH, it is 
classified under group 5 (i.e. Pulmonary Hypertension with Unclear Multifactorial 
Mechanisms) of the Updated Clinical Classification of Pulmonary Hypertension (Dana 
Point, 2008). (Simonneau et al., 2009) 
3. Epidemiology 
The prevalence of SAPH in general sarcoidosis population is 5% to 28% and varies with 
geographical location, clinical characteristics and diagnostic method. (Palmero & Sulica, 2010)   
In case series of unselected sarcoidosis patients, the prevalence of SAPH is as low as 5-15%. 
If only dyspneic patients are considered, SAPH frequency can be as high as 60%. 
(Baughman et al., 2011)  The prevalence of SAPH has been reported to be 73.8% in patients 
being evaluated for lung transplantation, with severe PH (mPAP >40 mm Hg) present in 
36% of patients. (Shorr et al., 2005)  SAPH is more prevalent in patients with advanced 
radiographic stage, but can develop in the absence of parenchymal lung abnormalities. In 
one cohort of 54 patients with sarcoidosis and elevated pulmonary pressures by 
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echocardiography, 60% of the patients had radiographic stage IV disease, while 10% had 
radiologically normal lung parenchyma (stages 0 and I). (Sulica et al., 2005)  When right 
heart catheterization (RHC) was used to measure mPAP, pulmonary hypertension was 
found in 31.8% of 22 patients without lung fibrosis. (Nunes et al., 2006)   
4. Pathophysiology 
Multiple mechanisms have been proposed to explain the development of pulmonary 
hypertension in patients with sarcoidosis. Pulmonary fibrosis with destruction of the 
pulmonary vascular bed and chronic hypoxemia is a major  cause of increased pulmonary 
artery pressures in advanced pulmonary sarcoidosis. Since SAPH may develop in the 
absence of pulmonary fibrosis, alternative pathogenic mechanisms have been proposed and 
include elevated levels of endothelin-1 (ET-1), decreased nitric oxide synthesis, structural 
abnormalities such as granulomatous vasculitis, pulmonary veno-occlusive disease, external 
compression of the pulmonary vessels by enlarged mediastinal lymph nodes, hypoxia-
induced vasoconstriction, and pulmonary vascular remodeling. In addition, a significant 
percent (i.e. approximately 30%) of patients with sarcoidosis have  elevated pulmonary 
artery pressures due to left heart disease.  (Baughman et al., 2010).    
Presence of multiple mechanisms of increased pulmonary pressures in sarcoidosis 
underscores the importance of different management and therapeutic options in SAPH. 
4.1 Nitric oxide 
The synthesis and release of nitric oxide (NO) from the endothelial cells and other sources is 
a key element in the maintenance of the low pulmonary artery vasomotor tone characteristic 
of the normal pulmonary circulation. (Sterling & Creager, 1999)  Decreased production of 
NO has been associated with the development of various forms of pulmonary hypertension. 
There is indirect evidence that a NO-dependent mechanism is operative in certain cases of 
SAPH. Inhaled NO administration acutely reduces the pulmonary vascular resistance (PVR) 
up to 20% in patients with SAPH, even in the presence of significant parenchymal lung 
disease. Although PVR reduction was not maintained over time, specific treatment targeting 
NO production might still be beneficial. (Preston et al., 2001) 
4.2 Endothelin-1 
Endothelin-1 (ET-1) is a peptide synthesized by the vascular endothelium with potent 
vasoconstrictor, pro-inflammatory and proliferative properties. This peptide has been found 
to contribute to increased pulmonary arterial tone and smooth-muscle proliferation in 
patients with pulmonary arterial hypertension. (Giaid et al., 1993)  Similarly, elevated levels 
of ET-1 in plasma, bronchio-alveolar lavage and urine have been found in SAPH. Moreover, 
ET-1 levels decrease with clinical remission of sarcoidosis. (Letizia et al, 2001; Reichenberger 
et al., 2001; Sofia et al., 1995; Terashita et al., 2006)  These findings suggest an important role 
for ET-1 in the pathogenesis of sarcoidosis and PH and raise the possibility of use of 
endothelin receptor antagonists in patients with SAPH. 
4.3 Granulomatous vasculitis   
Sarcoidosis is characterized by the presence of generalized granulomatous inflammation in 
organs and tissues, including the pulmonary vascular wall. This includes inflammation and 
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necrosis of the vessel wall with destruction of the elastic media of small and medium-sized 
vessels, with subsequent vascular remodeling and occlusive narrowing of the vascular 
lumen. These changes are reflected hemodynamically in elevated pulmonary vascular 
resistance and pulmonary hypertension. (Takemura et al., 1991, 1992)    
Granulomatous angiitis has been found in 69-100% of lung biopsies from patients with 
sarcoidosis, with a predilection for venous structures, although arterial involvement has 
been reported as well. (Rosen et al., 1977)  
4.4 Pulmonary veno-occlusive disease (PVOD)   
PVOD is an occlusive venopathy characterized by extensive and diffuse fibrosis of the 
intima of the venules and small intralobular veins. Recanalization occurs over time, 
resulting in chronic hemosiderosis and calcium deposition in the elastic laminae, altering the 
normal hemodynamics. These changes have been found in explanted lung specimens of 
patients with sarcoidosis, suggesting an association of a PVOD-like disease with the 
development of pulmonary hypertension in sarcoidosis. (Nunes et al., 2006)  Typical 
radiologic findings of PVOD, such as ground glass opacities and inter-lobular septal edema, 
have been frequently found in patients with SAPH, suggesting that PVOD accounts for 
some of the PVR increase seen in SAPH. (Handa et al., 2006; Nunes et al., 2006) 
4.5 Extrinsic compression of pulmonary vasculature  
Extrinsic compression of the pulmonary vasculature by enlarged lymph nodes may be 
associated with significant increases in PVR and mPAP if the vascular lumen is reduced 
more than 50%. Nunes et al. described extrinsic compression of large pulmonary arteries by 
lymphadenopathy in 21.4% of patients with sarcoidosis that developed pulmonary 
hypertension. It was typically attributed to bilateral mediastinal and hilar lymph node 
involvement. Sarcoidosis-associated mediastinal fibrosis can also contribute to external 
compression of the pulmonary vasculature. The diagnostic method of choice in cases of 
extrinsic pulmonary artery compression is pulmonary angiography, which demonstrates 
extrinsic pulmonary artery stenosis without intraluminal obstruction. (Damuth et al., 1980; 
Nunes et al., 2006; Wescott & DeGraff, 1973)  
4.6 Hypoxia-induced vasoconstriction  
Chronic hypoxemia and resulting pulmonary vascular remodeling are implicated in the 
pathogenesis of pulmonary hypertension in chronic parenchymal lung disease.  Correction 
of hypoxemia with supplemental oxygen has been shown to ameliorate the progression of 
pulmonary hypertension in patients with COPD. It is reasonable to extrapolate that patients 
with sarcoidosis and impaired pulmonary function, destruction of the lung parenchyma and 
hypoxemia are at similar risk for pulmonary hypertension by the same mechanisms.  
4.7 Pulmonary hypertension due to left heart disease 
Cardiac factors, either direct granulomatous myocardial involvement or left ventricular 
diastolic dysfunction with impaired relaxation have also been linked with increased 
pulmonary artery pressures in patients with sarcoidosis.  In these circumstances, pulmonary 
hypertension is postcapillary in nature (i.e. pulmonary venous hypertension). This 
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mechanism implies a different prognosis and requires different management strategies from 
precapillary SAPH treatment. (Baughman et al., 2006, 2010)  
5. Clinical presentation 
Persistent or progressive dyspnea on exertion in excess to that expected from the 
parenchymal lung involvement is the sentinel symptom of SAPH. (Handa et al., 2006; Nunes 
et al., 2006; Sulica et al., 2005)  Similarly, appearance or worsening of dyspnea in a patient 
with stable or improved pulmonary function or despite optimization of immunosuppressive 
therapy may suggest SAPH. (Baughman et al., 2010)  Other symptoms such as cough, chest 
pain, palpitations, and pre-syncope or syncope are suggestive, but not specific of SAPH. 
Less than 10% of patients with SAPH are asymptomatic. SAPH should be considered in 
patients presenting with syncope, although this symptom could also represent sarcoid 
cardiac involvement.  (Sulica et al., 2005)  Specific signs of pulmonary hypertension, such as 
a loud pulmonary component of the second heart sound, tricuspid or pulmonary 
regurgitant murmurs, and right-sided gallop may be present in SAPH. Signs of right 
ventricular failure, like lower extremity edema, right ventricular heave, and elevated jugular 
venous pressure, are present in 21% of the patients with SAPH. (Sulica et al., 2005) 
Hypoxemia and decreased functional status, measured by the 6-minute-walk distance, 
exercise desaturation and decreased distance-saturation product (DSP), tend to be more 
pronounced in patients with SAPH compared to sarcoidosis patients without PH. (Alhamad 
et al., 2010; Baughman et al., 2007; Bourbonnais & Samavati, 2008)   
6. Diagnosis 
Initial diagnosis of SAPH is based on a high index of suspicion.  If pulmonary hypertension is 
clinically suspected in patients with sarcoidosis, a comprehensive series of diagnostic tests 
should be performed to confirm the diagnosis and to exclude other causes of pulmonary 
hypertension. A 2- dimensional echocardiography is an appropriate initial step to screen for 
SAPH. Basic evaluation includes an electrocardiogram and laboratory tests, such as liver 
function tests, HIV testing, and markers of connective tissue disease. Ventilation-perfusion 
scan should be performed to rule out chronic thrombo-embolic pulmonary hypertension as an 
alternative explanation for pulmonary hypertension in these patients. Pulmonary function 
tests and tests of exercise capacity (such as the 6-minute-walk test or cardio-pulmonary 
exercise testing) are recommended to gauge baseline functional status of the SAPH patient.  
The gold standard for diagnosis of SAPH is right heart catheterization (RHC), although 
there are no published guidelines for which patients should undergo RHC in this patient 
population. Given the high prevalence of pulmonary venous hypertension in patients with 
sarcoidosis, RHC is the only reliable diagnostic method to differentiate precapillary SAPH 
from postcapillary PVH.  
We recommend that RHC be performed in all patients in whom SAPH is suspected, 
particularly if initiation of PH therapy is contemplated.  
6.1 Pulmonary Function Tests (PFTs)  
Compared to patients with sarcoidosis without PH, patients who develop SAPH tend to 
demonstrate more pulmonary functional abnormalities and a more pronounced reduction in 
the diffusing capacity of the lung for carbon monoxide (DLCO).  
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Forced vital capacity% (FVC %), forced expiratory volume in 1 second % (FEV1 %), mid-
expiratory flow (FEF 25–75), DLCO %, and total lung capacity % (TLC %) have been reported 
to be significantly lower in patients with sarcoidosis and PH when compared with patients 
without PH. (Baughman et al., 2007; Bourbonnais & Samavati, 2008; Handa et al., 2006; 
Sulica et al., 2005) 
A very common finding in patients with PH is the presence of a disproportionate decrease 
in the diffusing capacity of the lung for carbon monoxide to the degree of pulmonary 
impairment and restriction, similar to PAH associated with scleroderma.  
Decreases in DLCO% below 50% in the absence of radiographic pulmonary fibrosis and below 
30% in patients with stage 4 CXR may signify the development of SAPH. (Sulica et al., 2005)  
6.2 Six Minute Walk Test (6MWT)  
The six minute walk test is an inexpensive, simple and reproducible test used to assess the 
functional status of patients with pulmonary, cardiac and pulmonary vascular disease. Six 
minute walk distance is reduced in the majority of patients with sarcoidosis, and this 
reduction is even more pronounced in patients with SAPH, when compared with 
sarcoidosis patients without PH. (Baughman et al., 2007, Bourbonnais & Samavati, 2008)  In 
a prospective study of 142 patients with sarcoidosis, the median 6MWD walked by SAPH 
patients was 280 m, which was significantly lower compared to the median distance of 411 
m, walked by the patients without documented PH. (Baughman et al., 2007)   
In addition, compared to patients without PH, during a 6MWT, SAPH patients demonstrate 
more significant degree of oxygen desaturation, increased Borg Dyspnea Score and a lower 
distance saturation product (DSP, defined as the product between the distance walked and 
the lowest oxygen saturation achieved during the 6MWT). (Alhamad et al., 2010; Baughman 
et al., 2007; Bourbonnais & Samavati, 2008)  We recommend using the 6MWT at initial 
evaluation and periodically thereafter to monitor disease progression and response to 
therapy. However, it is important to recognize that, as opposed to patients with non-sarcoid 
pulmonary arterial hypertension (PAH), the clinical significance of the 6MWT results is more 
complex in SAPH patients. In these patients, other factors besides the presence of pulmonary 
vascular disease determine the 6MWD, such as the degree of desaturation with exercise, lung 
functional parameters (FVC), and self reported respiratory health. (Baughman et al., 2007) 
6.3 Radiology 
As mentioned above, SAPH is more frequently encountered in patients with advanced 
radiographic stage and pulmonary fibrosis. The role of high resolution chest tomography 
(HRCT) in diagnosing SAPH is unclear. Compared to controls with sarcoidosis but no PH, 
Nunes et al noted a more frequent occurrence of ground glass attenuation in patients with 
SAPH without fibrosis, and significantly higher frequency of septal lines in patients with 
SAPH and pulmonary fibrosis. Conversely, Handa et al were unable to correlate the 
presence of lymph node enlargement, lung opacities and thickening of bronchovascular 
bundles on HRCT with SAPH.  
Thus, pending additional results, at this time it is reasonable to conclude that  tomographic 
imaging studies are usually not helpful in predicting the presence of SAPH. (Handa et al., 
2006; Nunes et al., 2006) 
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6.4 Echocardiography 
Transthoracic echocardiography (TTE) is a noninvasive screening method commonly used 
to test for the presence of pulmonary hypertension in sarcoidosis. It is also helpful to detect 
other cardiac abnormalities, such as left heart disease, presence of shunts or pericardial 
effusion, and particularly to evaluate the right heart, anatomically and functionally. 
Echocardiography may be used to estimate the right ventricular systolic pressure (RVSP) 
from the tricuspid regurgitation jet velocity. Arcasoy et al reviewed 374 patients with 
advanced lung disease and found that RVSP could be estimated in only 44% of the subjects 
due to the lack of tricuspid regurgitant jet in the majority of patients. (Arcasoy et al., 2003). 
For the patients in whom RVSP estimation was feasible, even though there was a good 
correlation with RHC-determined RVSP  (r= 0.69, p<0.0001), the agreement was very poor.  
Notably, echocardiographically estimated RVSP differed from RHC measured RVSP by 
more than 10 mmHg in 52% of cases. This study suggests that echocardiography may be a 
useful screening tool for pulmonary hypertension, but may not be accurate enough for 
quantification of pulmonary artery pressures. As such, echocardiography cannot substitute 
right heart catheterization for the accurate diagnosis of SAPH. 
6.5 Right Heart Catheterization (RHC) 
RHC is the gold standard for diagnosis of SAPH and for determining the degree of right 
ventricular dysfunction. In a single-center series, 53 patients with sarcoidosis and persistent 
dyspnea despite systemic immunosuppressive therapy underwent right heart 
catheterization. Notably, TTE was unable to detect RVSP in 30% of these patients and 24% of 
the patients with elevated RVSP on TTE had PCWP greater than 20 mmHg. This study 
underscores the importance of RHC in precisely identifying and categorizing PH in 
sarcoidosis. (Baughman et al., 2006)  In a subsequent study, Baughman and colleagues 
performed RHC in 130 patients with sarcoidosis and unexplained dyspnea. They found that 
70 patients (53.8%) had PH. Of these, 20 patients (15.4 %) had postcapillary, pulmonary 
venous hypertension (PH with left ventricular disease), while 50 patients (38.5 %) had 
precapillary PH, with normal left-sided filling pressures. Importantly, the presence of PH 
was associated with a higher risk for death; patients with precapillary PH and post-capillary 
PH had hazard ratios for death of 10.39 and 3.14 respectively.  (Baughman et al., 2010)  In 
conclusion, RHC is of paramount importance in the diagnosis of SAPH, not only for 
establishing an accurate diagnosis, evaluation of the right ventricular function and ruling 
out pulmonary venous hypertension, but also for valuable prognostic information. 
7. Treatment 
There are no specific therapies or treatment guidelines currently available for the 
management of PH in association with sarcoidosis. The current management of these 
patients is based on PAH therapeutic options and from observational studies.  
7.1 Corticosteroids and immunosuppressive therapy 
Corticosteroids and other immunosuppressive agents have been long used for the treatment 
of sarcoidosis, but they do not have an established role in the treatment of SAPH. 
Gluskowski et al used RHC to study 22 patients with pulmonary sarcoidosis and 
radiographic stage 2 and 3 disease that were treated with corticosteroids for 12 months. 
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Radiological regression was seen in 91% of the patients. At baseline, 75% of the evaluated 
patients had elevated PAP with exercise and 16% had elevated PAP at rest. They found that 
half of the patients in each group had markedly reduced mPAP after treatment, but were 
unable to correlate corticosteroid treatment with changes in lung function, radiographic 
changes or mPAP decrease.  (Gluskowski et al., 1990) A possible explanation for the lack of 
uniform hemodynamic response to corticosteroids in this study is that, in patients without a 
hemodynamic response, healing of the intravascular granulomas with fibrosis resulted in 
further narrowing of the pulmonary vessels and permanently increased pulmonary vascular 
resistance.  
Nunes and colleagues found an even lower response to corticosteroids. They retrospectively 
studied 10 patients with SAPH treated with corticosteroids (oral prednisone 0.5 to 1 
mg/kg/day). These patients were evaluated at 3 and 6 months by Doppler 
echocardiography. In 3 of the 10 patients without evidence of pulmonary fibrosis they noted 
a decrease of more than 20% from baseline in RVSP by echocardiography. None of the 
patients with stage IV chest radiograph showed significant hemodynamic response to 
corticosteroids. (Nunes et al., 2006)  
7.2 Specific pulmonary hypertension therapy 
7.2.1 Prostacyclins  
Intravenous epoprostenol is a prostaglandin with potent vasodilatory activity and inhibitory 
effect on platelet aggregation used for the treatment of PAH. Fisher et al evaluated the long-
term effect of intravenous epoprostenol in 8 patients with moderate to severe PH (mean 
PVR > 1,176 dynes s cm-5) and WHO functional class III and IV symptoms. Majority of the 
patients showed evidence of pulmonary fibrosis, had restrictive physiology, decreased 
DLCO% and required supplemental oxygen. One of the 8 patients died from right heart 
failure prior to RHC. An acute vasodilator trial with intravenous epoprostenol was done in 
7 of the 8 patients. Six of the 7 patients demonstrated acute vasoreactivity defined as a 25% 
or more decrease in the PVR in response to maximally tolerated dose of epoprostenol. These 
6 patients were started on intravenous epoprostenol, but one died from cardiac arrest within 
hours of initiation. Five patients were followed for an average of 29 months while receiving 
intravenous epoprostenol (mean dose 55.6 ng/kg/min) and all showed functional 
improvement by 1 or 2 WHO classes. This limited evidence suggests that PAH therapies 
may be beneficial for SAPH patients. (Fisher et al., 2006) 
Inhaled iloprost, a prostacyclin analogue, has been administered as monotherapy to 22 
patients with SAPH in an open label prospective study. Fifteen patients completed 16 
weeks of iloprost administration, most common causes of discontinuation being cough 
and lack of compliance with 6-9 daily inhalations. Six patients showed hemodynamic 
improvement, with a more than 20% decrease in PVR. The 6MWD increased by more than 
30 m in 3 patients. Quality of life, as measured by the Saint George Respiratory 
Questionnaire, also improved in 7 of the SAPH patients who completed the study. 
(Baughman et al., 2009) 
7.2.2 Phosphodiesterase inhibitors 
Selective inhibitors of cGMP-specific phosphodiesterase type 5 (PDE5) increase local NO in 
the pulmonary vasculature, thereby promoting vasodilation and are currently approved for 
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the treatment of PAH. Only limited data is available for their use in SAPH. A small, single 
center retrospective study evaluated 25 patients with end-stage pulmonary sarcoidosis 
referred for transplantation. Twelve patients were treated with sildenafil for 1-12 months. 
Although there was no significant impact on the 6MWD, a significant reduction in mPAP 
(average mPAP for the group decreased from 48 mmHg to 39 mmHg), PVR (average PVR 
decreased from 10.7 to 5.6 Wood units), and an increase in the cardiac index from 2.3 to  
2.9 L/min/m2) was noted. (Milman et al., 2008) 
7.2.3 Endothelin receptor blockers 
Endothelin-1 receptor blockers are used in PAH to reverse the endothelin system activation, 
which results in deleterious vasoconstriction and cardiac and vascular remodeling. 
Increased levels of endothelin-1 have been found in patients with sarcoidosis that have 
developed PH, suggesting this might be a contributing mechanism to the development of 
SAPH.  Published experience with endothelin receptor blockers in SAPH is limited to a few 
retrospective case series and one prospective study.  
Baughman and colleagues evaluated 53 patients with sarcoidosis and persistent dyspnea 
and assessed their pulmonary pressures by RHC. Out of those, 5 patients with SAPH were 
treated with bosentan for 4 months, with a decrease in mPAP from 50 mmHg to 35 mmHg 
at follow-up. (Baughman et al., 2006; 2007) 
We have reported a retrospective case series of 40 patients with SAPH who received 
bosentan and were followed for an average of 38 months. These patients demonstrated a 
significant reduction in their mean PAP and PVRI at follow-up RHC. (P=0.0048 and P=0.017, 
respectively). We also observed an increase in the 6MWD of 74.6 m (p=0.0013) and less 
dyspnea. (Palmero & Sulica, 2011) 
Judson and colleagues enrolled 21 SAPH patients in a proof of concept prospective study 
designed to investigate the effect of ambrisentan therapy over 6 months. Ten patients 
completed the study. There were no significant changes in the 6MWD, gas exchanges or 
hemodynamic variables. However, there was a significant improvement in the WHO 
functional class and quality of life assessed by the Sarcoidosis Health Questionnaire. (Judson 
et al., 2011) 
7.2.4 Two-center experience 
Barnett et al evaluated 22 patients with SAPH treated with specific PAH therapeutic agents. 
These patients had moderate restrictive pulmonary dysfunction, severely decreased DLCO, 
radiologic stage IV disease (68%), and a mean PAP of 46 mm Hg. Following treatment with 
different PH agents (sildenafil, bosentan, and intravenous epoprostenol), there were 
improvements in WHO functional class, 6MWD (p=0.032), mean PAP (p=0.008) and PVR 
(p=0.011). Transplant free survival rates at 1 and 3 years were reported as 90% and 74%, 
respectively, and no serious adverse events were attributed to the any of the drugs. (Barnett 
et al., 2009) 
All these findings suggest a potential benefit from specific PAH therapeutic agents in 
selected patients with SAPH. However, large multicenter trials are required prior to 
recommending their use as standard of care in patients with SAPH.  
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8. Prognosis 
The development of PH reduces life expectancy in patients with sarcoidosis. Certain risk 
factors have been associated with worse outcomes and increased mortality. These factors 
include the presence of hypoxemia, mPAP above 35 mmHg, a cardiac index below  
2 L/min/m2, and high right atrial pressure ≥ 15 Hg. (Arcasoy et al., 2001; Shorr et al., 2002) 
9. Conclusion  
SAPH is common in advanced sarcoidosis, although it can be found in earlier stages of the 
disease as well. Presence of SAPH is usually associated with increased or unexplained 
dyspnea, decreased functional status, increased oxygen requirements, and lower survival 
rates. When clinically suspected, appropriate diagnostic tests, particularly echocardiography 
and right heart catheterization, should be promptly performed. There is a variable and 
inconsistent response to the available therapeutic agents in small series of patients with 
SAPH. Further studies are necessary to better understand this disease and to define more 
effective therapeutic strategies.  
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